The QualityStocks Daily Monday, July 23rd, 2018

Today's Top 3 StockMarketWatch

MarketClub Analysis (RETA) +64.98%

StockMarketWatch (DDE) +53.47%

TopPennyStockMovers (ICTV) +33.33%

The QualityStocks Daily Stock List

Nutritional High International, Inc. (SPLIF)

SmallCapVoice, CFN Media Group, Promotion Stock Secrets, and SECFilings.com News reported on Nutritional High International, Inc. (SPLIF), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Nutritional High International, Inc. centers on developing, manufacturing, and distributing products and nationally recognized brands in the hemp and marijuana-infused products industries. These include edibles and oil extracts for nutritional, medical, and adult recreational use. The Company works exclusively via licensed facilities in jurisdictions where such activity is permitted and regulated by state law. Nutritional High International is based in Toronto, Ontario.

Concerning its Hemp-Infused Products segment, Nutritional High International launched the first product in its Active Hemp category under the brand of “Nutritional Traditions”. For this segment, initial distribution will focus on California and Colorado through cannabis-related retail stores: medical marijuana dispensaries, vape lounges and headshops; and Food Supplement retail stores.

Regarding its Marijuana-Infused Products segment, Nutritional High concentrates on developing, acquiring, and designing Marijuana-Infused Products (MIPs) and Marijuana Concentrate products and brands. With this segment, the Company is establishing operations in Colorado and Illinois. It is working to expand into more U.S. States in support of its strategy to establish some of the first nationally-recognized brands for MIPs.

Nutritional High entered into an agreement to acquire the technology and Intellectual Property (IP) rights to a unique product to be referred to as the “Dab Stick”. The Dab Stick is a dispenser for viscous liquid substances. It can carry roughly 1⁄2 gram of cannabis oil extract designed with the retail consumer and adult use user in mind.

Nutritional High International announced this past March that it entered into a non-binding Letter of Intent (LOI) to acquire a 75 percent interest in Green Therapeutics LLC. Green Therapeutics is one of the premier innovators and established producer/processors within the cannabis space in Nevada.

Recently, NeutriSci International, Inc. and Nutritional High International announced the entry into a binding Memorandum of Understanding (MOU) to develop, manufacture, and distribute THC and CBD infused sublingual tablets employing NeutriSci’s patent pending technology, proprietary ingredients and formulations. NeutriSci is the innovator and pioneer behind neuenergy®.

NeutriSci and Nutritional High (subject to the negotiation of a definitive agreement) will develop products that will be manufactured and distributed by Nutritional High in U.S. States that allow the sale of cannabis infused products. The tablets will combine the benefits of NeutriSci and Nutritional High’s existing technologies and ingredient mixes.

Nutritional High International has signed a definitive agreement for the acquisition of Pasa Verde, a commercial scale cannabis oil extraction and edible facility in Sacramento, California. Pasa Verde produces several extract products on a contract manufacturing basis for top brands. It will start producing Nutritional High's FLÏ™ branded oil and edible products.

Last week, Nutritional High International announced its entry into a Letter of Intent (LOI) to acquire a 51 percent interest in Bright Green Lights LLC, a California company (d/b/a as J:MEDS). J:MEDS produces high quality cannabis-infused strain specific lozenges and sugar-free mints distributed throughout California. Nutritional High believes that its subsidiary Calyx Brands can substantially build sales of J:MEDS products. J:MEDS is a pioneer of “microdosed” infused products. It is one of California’s longest operating and most respected edible companies.

Nutritional High International, Inc. (SPLIF), closed Monday's trading session at $0.27, up 0.56%, on 46,966 volume with 24 trades. The average volume for the last 60 days is 96,952 and the stock's 52-week low/high is $0.0746/$0.9419.

chart

alpha-En Corp. (ALPE)

Amigo Bulls, OTC Markets, Business Insider, Real Pennies, InvestorsHub, GuruFocus, Barchart, MarketWatch, and Wall Street Mover reported on alpha-En Corp. (ALPE), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

alpha-En Corp. is a clean technology business whose shares trade on the OTC Markets Group’s OTCQB. The Company centers on enabling next generation battery technologies through developing and bringing to market high purity lithium metal and associated products produced in an environmentally sustainable manner. alpha-En is headquartered in Yonkers, New York.

The Company’s lithium metal is purer than what is now available on the market. It is free of all base metals and common non-conductive impurities found in the existing commercial supply.

Alpha-En enables next generation energy storage. The Company’s emphasis is on room temperature production of high purity lithium metal and associated products. Additionally, its flexible disposition method can streamline battery manufacturing, leading to battery production cost benefits.

The room temperature process requires minimal electricity. Moreover, using Lithium Carbonate as feedstock lessens the Company’s raw material costs. The process is conducted at 20°-30°C.

The room temperature, proprietary, patent pending process is mercury and chlorine free. This eliminates the use and release of toxic chemicals and expensive containment costs.

alpha-En is working on some collaborations to prove out and develop its technology. These include a joint research program with Mercedes-Benz Research and Development North America & Princeton University, and also with Argonne National Laboratory.

alpha-En and Cornell University have entered into a cooperative agreement to conduct sponsored research at the Baker Laboratory, under the direction of Mr. Héctor D. Abruña. Cornell University's agreement is for conducting vital analysis related to quantifying capacity and ion transport for the process of lithium thin film production patented by alpha-En.

The anticipation is that the collaboration will leverage the hi-tech facilities available at Cornell University, particularly the ability to study thin films of lithium "in operando", meaning – making movies, at the microscopic scale, of lithium film growth, as it happens in real time.

alpha-En believes its process for creating highly-pure lithium can be modified for diverse applications other than batteries. These derivative applications address very large markets and important environmental needs. The Company’s intention is to continue its research in these areas.

alpha-En Corp. (ALPE), closed Monday's trading session at $1.86, up 3.91%, on 5,900 volume with 15 trades. The average volume for the last 60 days is 1,964 and the stock's 52-week low/high is $1.19/$4.35.

chart

Helius Medical Technologies, Inc. (HSDT)

OTC Markets, Stockhouse, MarketWatch, and InvestorsHub reported on Helius Medical Technologies, Inc. (HSDT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Helius Medical Technologies, Inc. is a medical technology company based in Newtown, Pennsylvania. Its focus is neurological wellness and it works to develop, license, and also acquire innovative non-invasive treatments designed to amplify the brain’s ability to heal itself. NeuroHabilitation is a division of Helius Medical Technologies. NeuroHabilitation is developing a unique technology as a potential treatment for neurological symptoms caused by disease or trauma. Helius Medical Technologies’ shares trade on the OTC Markets Group’s OTCQB.

The Company’s intention is to file for U.S. Food and Drug Administration (FDA) clearance for the Portable Neuromodulation Stimulator (PoNS™). The PoNS™ device is an investigational non-invasive device designed to deliver neurostimulation by way of the tongue.

PoNS™ Therapy combines the use of the device with physical therapy. Currently, it is undergoing evaluation in a multicenter clinical trial for the treatment of balance disorder in patients with mild-to-moderate Traumatic Brain Injury (mTBI).

In 2013, The NeuroHabilitation division signed a Collaborative Research and Development Agreement (CRADA) with the US Department of Defense. This is to develop and manage clinical and regulatory activities for the PoNS™ device and CN-NINM technologies.

NeuroHabilitation successfully executed a sole source cost sharing contract with the U.S. Army Medical Research and Materiel Command (USAMRMC). The contract supports Helius’ registrational trial investigating the safety and effectiveness of the PoNS™. The PoNS™ is undergoing study in Canada for chronic balance and gait symptoms caused by Multiple Sclerosis.

Helius Medical Technologies announced in January 2017 that MedStar National Rehabilitation Hospital in Washington D.C. was launched as the sixth site to provide services supporting the Company’s ongoing pivotal trial investigating PoNS™ Therapy for the treatment of subjects with balance disorder resulting from mild-to-moderate Traumatic Brain Injury (TBI).

Clinical trial sites in the U.S. and Canada include Oregon Health and Science University in Portland, Oregon; Montreal Neurofeedback Center in Montreal, Quebec; Orlando Regional Medical Center in Orlando, Florida; HealthTech Connex, Inc. in Surrey, British Columbia; and Virginia Commonwealth University in Richmond, Virginia.

Recently, Helius Medical Technologies and the United States Army Medical Research and Materiel Command (USAMRMC) announced that the last subject was enrolled in the registrational clinical trial to investigate the safety and effectiveness of the PoNS™ device for the rehabilitation of chronic balance deficits caused by mild-to-moderate Traumatic Brain Injury (mTBI). The intention of the trial is to serve as the foundation for Helius to submit applications for marketing clearance in the U.S., Canada, and Europe for the PoNS™ device.

Last week, Helius Medical Technologies announced that via its wholly-owned subsidiary NeuroHabilitation Corporation (NHC), it has executed an extension to its Cooperative Research and Development Agreement (CRADA) with the US Army Medical Research and Materiel Command (USAMRMC) through 2018 and extended the deadline for commercialization of the PoNSTM Therapy to December 31, 2021.

Helius Medical Technologies, Inc. (HSDT), closed Monday's trading session at $9.48, up 8.22%, on 61,210 volume. The average volume for the last 60 days is 92,973 and the stock's 52-week low/high is $7.15/$20.70.

chart

Clean Coal Technologies, Inc. (CCTC)

InvestorsHub, Insider Financial, StockNewsUnion, Stock Invest, InvestorPoint, Small Cap Exclusive, Marketbeat, Investors Hangout, Stockhouse, and StocksTrade reported on Clean Coal Technologies, Inc. (CCTC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Clean Coal Technologies, Inc. is an emerging growth coal technology business. The Company holds patented process technology and other intellectual property (IP) that converts raw coal into a cleaner burning fuel. Its trademarked end products, "Pristine™" coals, are considerably more efficient, less polluting, more cost-effective, and provide more heat than untreated coal. Clean Coal Technologies is headquartered in New York, New York and the Company lists on the OTC Markets Group’s OTCQB.

The Company’s clean coal technology may lessen approximately 90 percent of chemical pollutants from coal. This includes Sulfur and Mercury. As a result, this resolves emissions issues affecting coal-fired power plants. Its technology deals with the extraction of the volatiles in liquid form from lower ranking coals.

Upon removal of moisture from the targeted coal, the liquid volatiles are utilized by way of an “absorption” process to fill the pores of the coal that have been dehydrated. More liquid volatiles are used through an adsorption process to coat the coal. The result is a significant improvement in the coal ranking via increased caloric content (BTU’s), and a stable low moisture feedstock for power generation.

Clean Coal Technologies has its Pristine-SA technology. This is a development stage technology designed to eliminate 100 percent of the volatile material in feed coal. Furthermore, the Company has its legacy technology, Pristine™. The design of it is to remove moisture and volatile matter (VM), as per client-specified requirements.

The Company’s Pristine M technology is a patented, low-cost coal dehydration technology. The Pristine M process starts with the extraction of volatile material in liquid form from lower ranking coals.

Clean Coal Technologies announced in January of this year that it was granted a divisional patent for its Pristine Technology in the People's Republic of China (PRC).

In May, Clean Coal Technologies announced that it was granted the required permits from Wyoming DEQ to start assembly of its test facility at Fort Union in Wyoming and go ahead with the testing of international coal.

Mr. Sean Mahoney, Press Officer of Clean Coal Technologies, said in May, “In addition to the testing of coal from Indonesia, India, Russia and the US we will be working closely with the University of Wyoming in advancing their efforts in coal by-products using our patented technology."

Clean Coal Technologies, Inc. (CCTC), closed Monday's trading session at $0.094, down 0.84%, on 164,292 volume with 23 trades. The average volume for the last 60 days is 114,882 and the stock's 52-week low/high is $0.06/$0.15.

chart

Northsight Capital, Inc. (NCAP)

AwesomePennyStocks, The Street, Equities, OTC Markets, Insider Monkey, Stockopedia, Equity Clock, Marketwired, Investors Hub, MarketWatch, Barchart, UptickNewswire, and WhaleWisdom reported on Northsight Capital, Inc. (NCAP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Northsight Capital, Inc. consists of a portfolio of online Cannabis-related websites, which are undergoing development and operated by the Company. These sites incorporate numerous aspects of the Cannabis industry. The Company is currently transitioning into two sectors. One is the Bitcoin ATM service industry. The other is its contemporary cannabis advertising and media platform. OTCQB-listed, Northsight Capital has its corporate headquarters in Scottsdale, Arizona.

The Company does not sell or distribute any cannabis products. Northsight is looking to acquire digital or publishing companies in the space.

Northsight Capital has its 420Careers.com. This is a leading job site in the Cannabis arena.  420Careers.com has 2,000 to 3,000 visitors each day. It has roughly 1 million page views each month.

Northsight also has its WeedDepot.com. This website provides consumers with a geo-targeted map directory of medical and recreational dispensaries, head shops, doctors, attorneys and more within the Cannabis industry. Weed Depot has an entire platform of content suited for every aspect of advertising and marketing to consumers from all businesses in the cannabis industry.

In November of 2017, Northsight Capital announced that it signed a preliminary agreement to acquire 80 percent of Westcliff Technologies. Presently, Westcliff operates a digital asset retail brokerage as “National Bitcoin ATM”. Furthermore, it provides consumers the ability to purchase Bitcoin immediately by way of a network of kiosks (ATM’s) located in the U.S.

Northsight Capital previously completed its acquisition of Crush Mobile, LLC. Crush Mobile has developed a group of dating sites with a presence in the Latino, Israeli, and African American communities.

Crush Mobile is now a part of Northsight Capital’s growing media group. In addition, Crush Mobile will be incorporating into its dating applications suite Northsight Capital's "Joint Lovers" dating app that will concentrate on the Cannabis space.

Northsight Capital announced this past January that it signed a non-binding Letter of Intent (LOI) to acquire Uptick Newswire, Inc. Uptick Newswire is one of the foremost outlets for micro-cap companies to display their company's current and future potential.

Last month, Northsight Capital announced the launch of its Joint Lovers dating app, precisely targeting the Cannabis space. The app is part of the Company's Crush Mobile Apps division that at present has about one million users combined. The apps are JCrush, MiCRush, Urban Crush and JointLovers. All apps are offering one free month with a year’s subscription that can be cancelled at any time.

Northsight Capital, Inc. (NCAP), closed Monday's trading session at $0.016, down 17.95%, on 475,915 volume with 12 trades. The average volume for the last 60 days is 96,697 and the stock's 52-week low/high is $0.018/$0.14.

chart

Scythian Biosciences Corp. (SCCYF)

OTC Markets, Stockwatch, YCharts, MicroSmallCap, PotNetwork, Penny Stock Picks, HighRisingStocks, Jet Life Penny Stocks, Marketwired, Stockhouse, MarketWatch, Barchart, InvestorIntel, Weed Newswire, Investors Hangout, The Street, and OTC Dynamics reported on Scythian Biosciences Corp. (SCCYF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Scythian Biosciences Corp.’s commitment is to advancing prevention and treatment efforts for concussion and traumatic brain injury with its proprietary cannabinoid-based combination drug therapy. Its mission is to be the first accepted drug regimen for the treatment of concussion. A research and development company, Scythian Biosciences is based in Toronto, Ontario. The Company lists on the OTC Markets Group’s OTCQB.

In addition, Scythian intends to develop other potential cannabinoid and non-cannabinoid based pharmaceutical products. This includes one that is in development for the treatment of gastro-inflammatory disease.

Scythian Biosciences is partnered with the University of Miami and its neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. Furthermore, the Company has started its worldwide expansion through launching additional cannabis-related activities internationally.

The Company is evaluating several strategic initiatives. In addition, it is pursuing partnerships with local cultivators, pharmaceutical import and distribution entities, and universities in North America, South America, and the Caribbean and beyond.

Scythian Biosciences’ first patent application covers a two-drug combination therapy for concussive treatment. That is, the combined use of an NMDA antagonist plus a CB2 agonist, either cannabinoid or non-cannabinoid.

Scythian Biosciences and its partners at the University of Miami Miller School of Medicine announced this month the results of a pre-clinical study evaluating the safety and efficacy of a cannabis derived combination therapy in the treatment of mild to moderate traumatic brain injury (TBI) in rodents.

This pilot study indicates an improvement in the cognitive functions of animals treated with a cannabinoid (CBD) derived combination therapy versus being treated with a vehicle, CBD alone, and HU211 alone. In addition, there were no adverse effects from either the combination therapy (CBD + HU211) or the individual components observed by scientists at the University of Miami Miller School of Medicine.

This month, Scythian Biosciences announced that it entered into a strategic deal with Aphria, Inc. for Aphria to acquire Scythian’s Latin American and Caribbean assets. The expectation is that the Company’s strategic relationship with Aphria will provide leverage for early stage investments in developing global markets. Aphria is a foremost global cannabis company.

Pursuant to a definitive share purchase agreement, Aphria will acquire 100 percent of the issued and outstanding common shares of LATAM Holdings, Inc. that following the closing of earlier announced transactions will own licenses and other assets held via subsidiaries in Argentina, Colombia and Jamaica. LATAM Holdings is a direct, wholly-owned subsidiary of Scythian Biosciences.

Scythian Biosciences Corp. (SCCYF), closed Monday's trading session at $2.95, up 6.12%, on 176,736 volume with 495 trades. The average volume for the last 60 days is 17,793 and the stock's 52-week low/high is $2.2875/$27.00.

chart

Marina Biotech, Inc. (MRNA)

Stock Twits, MarketWatch, InvestorsHub, Amigo Bulls, The Street, MicroCap Daily, Street Insider, Barchart, YCharts, OTC Markets, Zacks, and Marketbeat reported on Marina Biotech, Inc. (MRNA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Marina Biotech, Inc. concentrates on the development and commercialization of unique therapeutics for hypertension, arthritis, pain, and oncology. The Company’s commercial product is Prestalia®. It is approved by the US FDA (Food and Drug Administration) for the treatment of hypertension. Prestalia® is being commercialized through the DyrctAxess platform. OTCQB-listed, Marina Biotech is based in City of Industry, California.

Marina Biotech is developing and commercializing late stage, non-addictive pain therapeutics. The Company’s mission is to provide effective and patient centric treatment for hypertension. This includes resistant hypertension.

Marina Biotech is working to create a universal platform for the effective treatment of hypertension and for the distribution of fixed dose combination [FDC] hypertensive drugs such as Prestalia® and those in its pipeline. Prestalia® contains perindopril arginine, an angiotensin converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker. Prestalia® is indicated for the treatment of hypertension, to lower blood pressure.

Prestalia® is available to physicians and patients via bpCareConnect. This is a hypertension management program offered by Symplmed. Prestalia® may be used in patients whose blood pressure is not adequately controlled on monotherapy. Prestalia® may be used as initial therapy in patients likely to require multiple drugs to realize blood pressure goals.

Additionally, Marina Biotech is developing and commercializing late stage, non-addictive pain therapeutics. The design of its ‘next-generation of celecoxib,’ including IT-102 and IT-103, are to control the dangerous side-effects of edema that prohibit the drug from being prescribed at higher doses. IT-102 and IT-103 are the Company’s next generation celecoxib for management of arthritis pain.

Last month, Marina Biotech announced that each of Uli Hacksell, Ph.D. and Robert C. Moscato, Jr. were appointed to serve as a member of its Board of Directors. Dr. Hacksell was also appointed to serve as Chairman of the Board. Dr. Hacksell has agreed to devote half of his business time to Marina Biotech. Mr. Moscato presently serves as the Chief Executive Officer of the Company. Each of the appointments was effective July 1, 2018.

Marina Biotech, Inc. (MRNA), closed Monday's trading session at $0.62425, up 0.20%, on 583 volume with 7 trades. The average volume for the last 60 days is 5,990 and the stock's 52-week low/high is $0.52/$5.00.

chart

Mikros Systems Corp. (MKRS)

Chatter Box Stocks, OTCEquity, StockLockandLoad, PennyStockRumors.net, StockRockandRoll, PennyStocks24, AwesomeStocks, Wall Street Mover, PricelessPennyStocks, Promotion Stock Secrets, Marketbeat.com, Fast Money Alerts, Actual Gains, AddictivePennyStocks, StockBomb.com, ResearchOTC, Buzz Stocks, and OTPicks reported earlier on Mikros Systems Corp. (MKRS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Mikros Systems Corp. is a provider of advanced maintenance and monitoring solutions for mission-critical systems. The Company is an advanced technology enterprise, which designs and manufactures specialized electronic systems for the Department of Defense. Its primary business is to pursue and obtain contracts from the Department of Homeland Security, the U.S. Navy, and other governmental authorities. The Company is headquartered in Princeton, New Jersey, and has its Manufacturing and Depot Center in Largo, Florida.

Mikros Systems has developed, delivered, and installed military-grade equipment to Federal customers for greater than three decades. The Company’s capabilities include technology management, electronic systems engineering and integration, radar systems engineering, command, control, communications, computers and intelligence systems engineering, and communications engineering.

Mikros produces advanced maintenance systems for the Navy. These include the ADEPT Maintenance Automation Workstation and the ADSSS Condition Based Maintenance system for the Littoral Combat Ship. ADEPT systems are in use daily for performance optimization of advanced radar systems.

Mikros Systems’ Lifecycle Support capability is centered on ensuring the systematic interactions between Integrated Logistics Support (ILS), Depot, and Field Support activities are integrated to accomplish the highest levels of system readiness. The Company purchased certain software products, intellectual property (IP) and related assets from VSE Corp. The main software programs purchased by Mikros are the Prognostics Framework (PF) and Diagnostic Profiler (DP) programs.

The Diagnostic Profiler software is used around the world by many multinational companies for optimized maintenance of varied product lines. Diagnostic Profiler is also used by the U.S. Air Force for depot test programs.

Prognostics Framework is used by the U.S. Army for many missile defense systems. These software products provide Mikros Systems with the opportunity to service commercial customers and additional Department of Defense customers outside the Navy.

In August, Mikros Systems and Elliott-Lewis Corporation announced that they entered into a Memorandum of Understanding (MOU) to offer a condition-based maintenance solution for Heating Ventilation, Air Conditioning and Refrigeration (HVAC) equipment. Mikros Systems will provide hardware and software development, system integration, and test services based on its proprietary Prognostics Framework solution.

Elliott-Lewis will provide subject matter expertise and technical consulting services for requirements definition, on-site installation and testing. At present, Mikros and Elliott-Lewis have two active pilot systems, which are providing key maintenance data on a daily basis to their technicians.

This week, Mikros Systems announced that it received funding of $548,000 from Naval Surface Warfare Center, Crane Division (NSWC Crane) for additional sustainment services for the Adaptive Diagnostic Electronic Portable Testset (ADEPT) workstation. With this contract, Mikros will install software performance enhancements and updates to ADEPT systems. Year-to-date, Mikros Systems has received more than $3.2 million in U.S. Navy funding to support production, engineering, and also technical support of the ADEPT product line.

Mikros Systems Corp. (MKRS), closed Monday's trading session at $0.51, up 3.24%, on 2,300 volume with 3 trades. The average volume for the last 60 days is 26,408 and the stock's 52-week low/high is $0.30/$0.57.

chart

MariMed, Inc. (MRMD)

OTC Markets reported on MariMed, Inc. (MRMD), and today we report on the Company, here at the QualityStocks Daily Newsletter.

MariMed, Inc. is an industry leader in the design, development, operation, funding, and optimization of medical cannabis cultivation and production centers and dispensaries. The Company provides turnkey solutions to cannabis cultivators, producers, and dispensaries. It specializes in solutions for securing and operating facilities, manufacturing and processing, dispensary, layouts, and designs, merchandising and sales. MariMed is based in Newton, Massachusetts.

Worlds Online (MRMD) formerly (WORX) acquired the remaining 49 percent stake in MariMed Advisors for 75 million shares of common stock (restricted for 12 months), bringing its ownership of the subsidiary to 100 percent. Worlds Online changed its name to MariMed, Inc.

The Company is concentrating exclusively on serving the quick expanding $7 billion legal cannabis industry. MariMed will spin out Worlds Online’s legacy 3D virtual community business to a newly created subsidiary corporation.

MariMed reported strong revenue growth for 2016 that continued into this year. MariMed more than doubled revenue in 2016 over 2015, increasing from $1.27 million in 2015 to $3.56 million in 2016. Most of the revenue was attributable to subsidiary MariMed Advisors and its cannabis services and products business.

MariMed is on the leading edge of medical research, working to create precision dosed products to treat specific conditions. Its team has developed state-of-the-art and regulatory compliant facilities in many states. These facilities are replicable and scalable models of excellence in horticultural principals, cannabis production, product development, and dispensary operations.

MariMed’s services include application assistance, real estate and safe access, build-out and ongoing consultation, business acceleration solutions, and physician and patient outreach. MariMed Advisors, Inc. has a portfolio of high-quality branded products, product development plans, product packaging, as well as product licensing opportunities.

MariMed provides a complete range of consulting services in the medical cannabis industry. It uses a systematic approach, from the permit and application process, to on-time operational readiness. As Cannabis experts, it specializes in supporting the development of high quality state-licensed, medical cannabis dispensaries and cultivation facilities.

Today, Tikun Olam, the world pioneer in cannabis research, and MariMed announced an expansion of their licensing agreement for Tikun Olam products to be grown, manufactured, and also sold via MariMed's network of managed and affiliated licensed facilities across the U.S. The new agreement brings Tikun Olam's premium cannabis products, years of proprietary, peer-reviewed scientific research, and unprecedented clinical data collection to four additional MMJ-legal U.S. states.

Tikun Olam and MariMed's relationship started in 2015 with a pilot program in Delaware. It marked the first time that U.S. patients had access to the world's only cannabis strains proven to deliver symptomatic relief for specific conditions including cancer, PTSD, epilepsy, Crohn's Disease/Colitis, chronic pain and neuropathy, among others.

MariMed, Inc. (MRMD), closed Monday's trading session at $2.921, up 3.58%, on 223,641 volume with 383 trades. The average volume for the last 60 days is 384,075 and the stock's 52-week low/high is $0.201/$4.07.

chart

Medicine Man Technologies, Inc. (MDCL)

The Street, MarketWatch, Marketwired, CFN Media Group, and Stockhouse reported on Medicine Man Technologies, Inc. (MDCL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Medicine Man Technologies, Inc. represents and licenses the cultivation and dispensary Intellectual Property (IP) of Medicine Man - a well-respected Tier III operator in Colorado. Medicine Man Technologies provides cultivation consulting services for cannabis growing technologies and methodologies. The Company is one of the nation’s top cannabis brand development and consulting enterprises. Established in 2014, Medicine Man has its headquarters in Denver, Colorado.

Medicine Man works closely with industry-leading extraction partners. These partners provide the required licensing service support and formulations to help customers with their planned deployment of a successful processing facility.

The Company is centering on working with clients to use its experience, technology, and training to help secure a license in states with newly emerging regulations. In addition, it is focusing on deploying its highly effective variable capacity constant harvest cultivation practices through its deployment of Cultivation MAX, and eliminating the liability of single grower dependence.

Medicine Man is also continuing the expansion of its Brands Warehouse concept. Additionally, the Company engages in retail operations of cannabis products. It also provides general business and referral management for other related service providers for its customers. It cultivates and sells via its parent company Medicine Man Denver, the largest cultivation/retail facility in Colorado.

Medicine Man’s risk-averse cannabis cultivation technology delivers consistent, high quality, high yield production within a clean-room style environment. The Company’s state-of-the art dispensary model ensures patients and consumers have safe and secure access to an array of medical and/or recreational cannabis products.

Recently, Medicine Man Technologies announced the definitive agreement to acquire Denver Consulting Group, LLC was executed by the parties on July 21, 2017. This acquisition became effective on July 24th upon the filing of applicable documents with the Colorado Secretary of State. Denver Consulting Group has offices in Denver, Colorado, and Portland, Oregon.

Mr. Brett Roper, Medicine Man Technologies’ Chief Executive Officer and Co-Founder stated, “We are encouraged by the level of interest the ownership of the Denver Consulting Group has expressed in our forward planning, especially in our Cultivation MAX and Success Nutrient lines of business which we are expanding nationally. We believe that they will play a valuable role in our expansion and we are excited about the growth opportunities this consolidation will provide to our evolution as a Brands Warehouse.”

Medicine Man Technologies, Inc. (MDCL), closed Monday's trading session at $1.21, up 0.83%, on 5,413 volume with 21 trades. The average volume for the last 60 days is 42,532 and the stock's 52-week low/high is $0.92/$3.40.

chart

Right On Brands, Inc. (RTON)

PennyStockVault, InvestorsHub, MarketWatch, OTC Markets, YCharts, Barchart, Stockhouse, Capital Cube, Investors Hangout, SmallCapVoice, and Investors News Magazine reported on Right On Brands, Inc. (RTON), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Right On Brands, Inc. is a consumer goods company listed on the OTC Markets’ OTCQB. It specializes in the brand development of health conscious, hemp-infused food and beverage products. Right On Brands consists of three subsidiaries. These are Endo Brands, Humbly Hemp, and Humble Water Company. Right On Brands has its corporate headquarters in Santa Monica, California.

The Company is developing, marketing, and investing in industrial hemp, cannabis, adaptogenic superfoods and natural water for a new generation of health-conscious consumers. Endo Water is pH balanced and micro-clustered for antioxidant protection. In addition, it is oxygenated for improved performance and energy.

Endo Water is infused with a 99.5 percent pure CBD oil, processed using Nano Technology. This makes the particles one-millionth of its normal size. The process permits the Nano-Sized CBD's to immediately penetrate one’s cells in comparison to the lengthy process of being absorbed by the body's digestive system.

The Humble Water Company product is a natural spring water sourced from an ancient ice age aquifer at the foothills of the Rocky Mountains situated at the only triple watershed in North America. Humble Water is high in natural alkalinity and is pure.

Humbly Hemp is a product line of hemp-based products. Each Humbly Hemp bar is kosher, vegan, soy free, dairy free, and gluten-free. They are also free of all top 11 allergens. The foundation of the Company’s protein bars is with gluten free rolled oats, hemp seeds, and plant protein.

Right On Brands has established a joint venture (JV) with Centre Manufacturing, LLC to create ENDO Labs. ENDO Labs was formed to fill the void in the hemp derived CBD market for the creation and manufacturing of quality formulated CBD products.

ENDO labs can formulate food, beverage, skin-care/topical, supplements, pet, and can take on advanced formulations and products to any customers’ preference. Furthermore, ENDO Labs will have the function of brokering CBD oil for its customers and clients. Right On Brands will have 51 percent ownership of the JV with Medical Biochemist Dr. Ashok Patel's Centre Manufacturing.

Right On Brands is starting marketing and sales distribution of the ENDO Brands product line this month in Nevada. This is the Company’s first attempt to expand beyond California.

Additionally, Right On Brands has expanded distribution by partnering with Pioneer Sales/Pioneer Food Group with operations in East Longmeadow, Massachusetts and Denver, Colorado. Pioneer has already acquired inventory. It is in the process of distributing ENDO Brands and Humbly Hemp products to their existing retail accounts. Pioneer's Sales Company represents a select group of brands to broker. It distributes to health food/grocery, convenience stores, food service, military, hospital, as well as the travel industry.

Right On Brands, Inc. (RTON), closed Monday's trading session at $0.135, down 3.50%, on 25,168 volume with 3 trades. The average volume for the last 60 days is 12,464 and the stock's 52-week low/high is $0.0721/$0.70.

chart

Humanigen, Inc. (HGEN)

InvestorsHub, OTC Markets, AmigoBulls, Barchart, TradingView, Investopedia, Investors Hangout, and Financial Times reported on Humanigen, Inc. (HGEN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A biopharmaceutical company, Humanigen, Inc. concentrates on advancing medicines for patients with neglected and rare diseases via innovative, accelerated business models. Lead compounds in the Company’s portfolio include benznidazole, and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Humanigen has its headquarters in Brisbane, California. The Company lists on the OTC Markets Group’s OTCQB.

Benznidazole is for the potential treatment of Chagas disease in the United States. Chagas disease is a parasitic infection caused by a protozoan organism named Trypanosoma cruzi, which affects millions of people mainly in rural areas of Mexico, Central and South America.

Lenzilumab has potential for treatment of various rare diseases. This includes hematologic cancers such as chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML). Lenzilumab is a Humaneered® recombinant monoclonal antibody. It neutralizes soluble granulocyte-macrophage colony-stimulating factor (GM-CSF), which is a critical cytokine that propels the growth of certain hematologic malignancies.

Ifabotuzumab is a first-in-class, monoclonal antibody. It targets the EphA3 receptor tyrosine kinase created utilizing Humanigen's proprietary Humaneered® technology.

In early August, Humanigen announced that it completed enrolment and follow-up of subjects in its human bioavailability study for benznidazole. The bioavailability study is an important part of its planned New Drug Application (NDA) package to the U.S. Food and Drug Administration (FDA) in the 505(b)(2) development program for benznidazole as a potential treatment for Chagas disease. The study’s primary aim is to characterize the pharmacokinetic profile of benznidazole.

In early August, Humanigen announced it appointed Mr. Greg Jester as the Company’s Chief Financial Officer (CFO), effective September 5, 2017. Mr. Jester brings over 20 years of financial, operational management, as well as entrepreneurial experience in the life sciences industry.

He will be responsible for further strengthening Humanigen’s financial foundation to facilitate the Company’s next growth phase. Most recently, Mr. Jester served as Vice President, Finance, for Tris Pharma.

Humanigen, Inc. (HGEN), closed Monday's trading session at $0.62, up 1.66%, on 8,532 volume with 11 trades. The average volume for the last 60 days is 4,629 and the stock's 52-week low/high is $0.125/$2.60.

chart

The QualityStocks Company Corner

Virtual Crypto Technologies Inc. (OTCQB: VRCP)

The QualityStocks Daily Newsletter would like to spotlight Virtual Crypto Technologies Inc. (VRCP).

Virtual Crypto Technologies Inc. (OTCQB: VRCP) is making it easier for people to finance their needs through virtually deregulated but still-confident peer-to-peer money networks that allow the rapid exchange of bitcoin and cash on a bi-directional ATM platform. New press materials, titled “Cryptocurrency and Blockchain Innovators Poised to Reap Rewards as Fintech Reshapes How Money Is Used” (audio: http://nnw.fm/z74Ex; text: http://nnw.fm/7Q4s5), highlight how the company is helping to rapidly transform the financial industry by reshaping how money is used at the most basic level.

Virtual Crypto Technologies Inc. (OTCQB: VRCP) is a developer of software and hardware for the purchase and sale of cryptocurrencies through ATMs, tablets, PCs and mobile devices. The company’s proprietary algorithmic technology trading platform, called NetoBit Trader, can instantaneously confirm the purchase or sale of Bitcoin, a process that typically can take between 10 minutes to 24 hours. All trades and exchanges are insured up to $3,000 per trade. The global cryptocurrency ATM market is predicted to surpass $285 million by 2025, yet, at present, only 30 percent of these machines allow two-way trades.

With NetoBit Trader, cryptocurrency holders enjoy immediate confirmation of Bitcoin and its crypto equivalents at the best crypto exchange rate at the point of transaction – providing a major breakthrough in the quest to bring cryptocurrencies to the mass market. Virtual Crypto’s cryptocurrency ATM, embedded with currency exchange transaction validation (CETV) in its hardware and software, accepts and dispenses cash and cryptocurrency in seconds.

Virtual Crypto’s NetoBit Trader and mobile retail point-of-sale platform incorporates advanced technologies tailored to the needs of primary market players, users, investors, and business owners. Virtual Crypto’s platform bridges the three main functions of the cryptocurrency sector – exchanges, wallets and payments – to the world of fiat exchanges, granting access to immediate cash exchanges between consumers and businesses worldwide.

NetoBit Trader’s over-the-counter, two-way transaction solution is available through one app, providing online cryptocurrency transactions at ecommerce and gaming portals. The app provides real-time cryptocurrency validation and exchange, easy buying and selling of Bitcoin with cash, enables traders to buy and trade crypto, and gamers to transfer cryptocurrency into cash after play. Crypto users can withdraw funds from their crypto accounts through a NetoBit cryptocurrency ATM or software-enabled tablet, and consumers can purchase retail with crypto from businesses that offer and use the NetoBit software.

The company’s newly redesigned corporate website, www.virtual-crypto.com, delivers a simple, clean design with enhanced functionality, features and navigation. Virtual Crypto’s new corporate website includes:

  • Downloadable NetoBit Trader app link and contact forms for more information
  • MarketWatch provides real-time tracking of the Bitcoin market, with other currencies to follow
  • Improved security utilizing https certificates to protect personal information and site integrity
  • Media room with downloadable product brochures, corporate presentations and other relevant content
  • Investor’s page provides transparency to investors with direct access to Virtual Crypto’s progress through press releases, SEC filings, senior management team bios, and stock performance charts
  • Social Media integration with buttons for LinkedIn, Twitter and Facebook jump to Virtual Crypto’s social media profiles, providing real-time updates from the online community

“Our primary objective is to make cryptocurrencies accessible to everyone, and that was the motivation for our redesign,” said Alon Dayan, Chief Executive Officer of Virtual Crypto. “The updated content provides real value for our customers, shareholders and employees, showcasing our products and services, in an intuitive, easy to navigate way.”

Virtual Crypto’s strategic vision of “Cryptocurrency Made Easy” allows crypto traders and users to overcome the complex hurdles currently hampering the cryptocurrency sphere.

Virtual Crypto Technologies Inc. (VRCP), closed the day's trading session at $0.12, up 31.88%, on 56,707 volume with 24 trades. The average volume for the last 60 days is 36,533 and the stock's 52-week low/high is $0.0125/$0.38.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

At Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) 2018 Annual General Meeting, all motions were passed. The company is proceeding on schedule with its reorganization into four new wholly owned subsidiaries to serve the nicotine, hemp, pharmaceutical and cannabis industries. All of these subsidiaries will utilize the company’s patented DehydraTECH® proprietary absorption technology for application to their own sectors (http://nnw.fm/5NnGk).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.70, up 4.29%, on 120,449 volume with 227 trades. The average volume for the last 60 days is 245,449 and the stock's 52-week low/high is $0.30/$2.54.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (TSX: TGOD).

CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces the launch of a new weekly news show, CFN Weekly. The Green Organic Dutchman (TSX:TGOD) which recently became the world’s largest cannabis initial public offering was spotlighted in the latest episode. In conjunction with its listing, the company recently launched a new global division focused exclusively on the beverage industry.

The Green Organic Dutchman (TSX: TGOD) (OTCQX: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (TSX: TGOD), closed the day's trading session at $6.03, up 4.15%, on 488,000 volume. The stock's 52-week low/high is $3.50/$8.28.

Recent News

chart

Medical Cannabis Payment Solutions (OTC: REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG).

Medical Cannabis Payment Solutions (OTC: REFG) is intensifying its focus on cannabis as research firm Arcview Market Research projects that the growth of the legal cannabis industry will re-accelerate in 2018 in North America as adult use sales grow in Canada, California and Massachusetts, along with first time medical cannabis sales in Florida (http://nnw.fm/tS8xp).

Medical Cannabis Payment Solutions (OTC: REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company’s state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company’s unique “StateSourced” proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven’t been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin’s cryptocurrency ($Weed) with Medical Cannabis Payment Solutions’ StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

“We’ve completed our transition from development stage to revenue stage,” says Roberts. “We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases.”

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry.

Medical Cannabis Payment Solutions (REFG), closed the day's trading session at $0.04, off by 2.44%, on 138,088 volume with 36 trades. The average volume for the last 60 days is 542,958 and the stock's 52-week low/high is $0.0161/$0.092.

Recent News

chart

EVIO, Inc. (OTCQB: EVIO)

The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO).

EVIO Inc. (OTCQB: EVIO), an accredited and established leader in cannabis testing, is set to exhibit at one of the nation’s foremost cannabis trade shows. EVIO will have booth #1113 at the National Cannabis Industry Association’s (NCIA) 5th Annual Cannabis Business Summit & Expo coming to San Jose, California, on July 25-27 (http://nnw.fm/ms8PN).

EVIO, Inc. (OTCQB: EVIO), via the EVIO Labs division, is the nation’s leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation’s cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation’s leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today’s fastest growing industry.

EVIO, Inc. (EVIO), closed the day's trading session at $1.00, even for the day, on 42,372 volume with 43 trades. The average volume for the last 60 days is 95,193 and the stock's 52-week low/high is $0.47/$2.70.

Recent News

chart

GreenBox POS, LLC (OTCQB: GRBX)

The QualityStocks Daily Newsletter would like to spotlight GreenBox POS, LLC (GRBX).

GreenBox POS, LLC (OTCQB:GRBX) (“GreenBox,” “GRBX,” the “Company”) is pleased to announce that TrustGateway, a major component of the Company’s QuickCard payment system, is proving to be highly efficient in preventing fraud on the GreenBox payment platform.

GreenBox POS, LLC (OTCQB: GRBX) is a hardware and software technology company that builds customized payment solutions in different industries. The company is headquartered in San Diego, California, with offices in Seattle, Wash.; Las Vegas, Nevada; and Vancouver, British Columbia, Canada. GreenBox, which has been awarded five provisional patents for its blockchain-based technology, delivers a fully integrated, intuitive, easy-to-use, point of sale (POS) system for a variety of businesses across a multitude of different market sectors.

GreenBox develops all software in-house and with international subsidiaries, which allows the company to provide individualized electronics modifications in partnership with different vendors. Custom POS machines are available as an upgrade from existing solutions currently in use. First-time merchants can also take advantage of custom-built kiosk machines powered by blockchain technology, complete with e-wallet integration downloadable via Android or iOS apps, or via installed cash-loading kiosks.

GreenBox develops POS (point of sale) software and hardware solutions; DEL (delivery app, APIs to POS and PAY); PAY (payment app, providing financial APIs to all other components); and KIOSK (deposit, cash and E-wallet management). The following flagship products, services and custom hardware are currently available:

  • QuickCard – the QuickCard kiosk handles all cash issues, both for cashless operations and for legacy cash; performs direct and immediate deposits from cash to blockchain and confirms bank account availability within minutes. Accepts cash, debit/credit cards, or ACH directly to most banks while settling funds instantly. All records are stored securely on blockchain. No faster deposit solution is available in the regular and non-traditional banking systems (unless depositing cash directly into a cash machine connected to a bank branch).
  • POS Solutions – GreenBox software, developed in-house and with international subsidiaries, features operational compliance, financial audit prep, expense tracking, tax payments, register-specific features, and data fidelity controls (backup/restore, cloud security, privacy, etc.). GreenBox POS software is fully integrated with Del and Pay Systems and features front register mode and back-end admin mode, in addition to in-admin mode to manage employees, vendors, expenses, taxes and compliance. All records are stored on blockchain with data reliably secured and protected.
  • LOOPZ – This delivery software solution offers service dispatcher back-end technology with manual and automatic modes. The software is uniquely designed to be effectively utilized for mobile delivery service operations with full autonomous dispatch capabilities. LOOPZ provides the following features: two mobile apps (driver and consumer) running on Android and IOS; direct reporting to point of sale inventory and use of pay for instant settlements; separate escrow setup for tips and merchant sale; all data and information is securely hosted on a blockchain platform.

The management team at GreenBox includes CEO Fredi Nisan, who comes from the POS and merchant services business sector. He recently completed a successful exit in the POS and ERP business, which he founded and managed through the exit. Joining Nisan is Ben Errez, executive vice president, who comes from the investment, consulting and big software and hardware industries. His previous executive roles include positions at Microsoft (including engineering management of Microsoft Office for complex scripts); IBM (with which he had an exit); and Intel. Errez has also consulted the world’s biggest private economy, World Trade Center, on payment systems, security, reliability and privacy of software and hardware development.

GreenBox POS, LLC (GRBX), closed the day's trading session at $0.52, even for the day, on 36,849 volume with 21 trades. The average volume for the last 60 days is 23,916 and the stock's 52-week low/high is $0.017/$0.8999.

Recent News

chart

FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRANKFURT: TQ42)

The QualityStocks Daily Newsletter would like to spotlight FANDOM SPORTS Media Corp. (FDMSF).

FANDOM SPORTS Media (CSE:FDM) (OTC:FDMSF) (FRANKFURT:TQ42) announces it has signed a two-year agreement with LehmanBush, a consulting and investment advisory firm headquartered in Beijing, China.

FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRA: TQ42) taps into the primal, unfiltered passion of sports fans from around the world by providing an uncensored social media platform delivered through the FANDOM SPORTS mobile app. As an aggregator, curator and instigator of both company-created and user-generated content, the FANDOM SPORTS app is designed to entertain sports enthusiasts with real-time, interactive content on a mobile only app that offers bragging rights and real-life rewards. True sports addicts will appreciate an app that allows fans to pick a fight or create their own FanFights and rule over others as they trash talk their way to victory. The FANDOM SPORTS proprietary data centric “argument engine” measures and scores opinionated dialogue, as well as establishes consensus, giving fans and users the ability to dive deeper into one-of-a-kind cultural moments, cheer on favorite sports teams and slam dunk some sweet rewards.

Building on the company’s tag line – “Pick a Fight” – the FANDOM SPORTS app provides an always fresh, authentic rush of deeper-than-surface interactive content that resonates with the targeted age demographic of 18-34. Intense sports fans aren’t afraid of stepping up to the plate to engage other users by unleashing their opinions within the app’s structured debate resolution tool coined “FanFights.” Sports-loving fans can explore, gloat, vote, invite friends, create provocative FanFight topics and play to win while inside the FANDOM SPORTS app, which is currently available in the Apple App store and coming to the Google Play store imminently. The company’s self-learning algorithm predicts and collects user preferences while building relevant personalized FanFight channels, bringing the concept of competitive, in-your-face conversation to a whole new level of sports entertainment.

The FANDOM SPORTS app is free to play (F2P) with in-app purchase and subscription capabilities. The gaming aspect of the ecosystem is built on behavioral economics and delivers multiple revenue streams by maximizing average revenue per daily active user (ARPDAU) and user-generated content (UGC), with select placement of high-impact video and moment-based marketing as part of the brand-sponsored FanFights and in-app offers. The global platform enables applications (either FANDOM SPORTS created or 3rd party apps) to be operated in partnership with leading sports themed brands, leagues, and service providing companies within three verticals – live action, eSports, & fantasy – from around the world by supplying “interactive sports entertainment” to fans. The FANDOM SPORTS platform creates a bullet-proof snapshot of the app’s fan base through a Blockchain supported “PlayerCard” in tandem with the “Engagement Score”, which doubles as an invaluable acquisition and retention tool for its business operators. FANDOM SPORTS hosted transactions are placed on the distributed ledger, making them immutable and public to verified users interacting within the business ecosystem. Tracking this digital footprint provides extremely valuable metadata generated by users’ very dynamic behavior and sports passion.

FANDOM SPORTS’ Brand and Sponsorship partners are harnessing the affluent sports fans age 18-34 with integrated marketing content and service experience. The moments-based marketing integration will translate through FanCoin redemption, in exchange for items provided by programs established by FANDOM SPORTS and its clients. These programs are a key part of the business model and covers, as an example, the following partners; Sports Leagues, TelCo’s service offerings, and Content owners (i.e. FANDOM SPORTS provides new paying customers to the owners of pay-per-view platforms).

“Pick A Fight. Talk Trash. Get Rewarded.”

FANDOM SPORTS Media is an entertainment company that aggregates, curates and produces unique fan-focused content.

The FANDOM SPORTS App is the Company’s core product, which is the ultimate destination for unfiltered raw sports talk. The app allows passionate sports fans to unleash their primal sports passions, pick fights and earn rewards.

So download the app and bring your crew. Talking trash is better with friends. The more you invite, the more FanCoins you earn.

You may also visit the Company’s website at www.fandomsportsmedia.com or contact them directly at info@fandomsportsmedia.com.

DISCLAIMER:

The CSE has not reviewed and does not accept responsibility for the adequacy and accuracy of this information. This news release may contain forward-looking statements. These forward-looking statements do not guarantee future events or performance and should not be relied upon. Actual outcomes may differ materially due to any number of factors and uncertainties, many of which are beyond the Company’s control. Some of these risks and uncertainties may be described in the Company’s corporate filings (posted at www.sedar.com).

The Company has no intention or obligation to update or revise any forward-looking statements due to new information or events

FANDOM SPORTS Media Corp. (FDMSF), closed the day's trading session at $0.0698, even for the day. The average volume for the last 60 days is 9,851 and the stock's 52-week low/high is $0.0601/$0.2864.

Recent News

chart

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

The QualityStocks Daily Newsletter would like to spotlight Foresight Autonomous Holdings Ltd. (FRSX).

Development stage technology company Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) through wholly owned subsidiary Foresight Automotive Ltd., has been developing proprietary stereoscopic technology that delivers real-time information to prevent accidents. To view the full article, visit: http://nnw.fm/e0jKk.

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.

Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.

The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.

Foresight has developed three main products:

  • QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
  • Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
  • Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.

Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.

Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.

Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.

Foresight Autonomous Holdings Ltd. (FRSX), closed the day's trading session at $3.016, off by 1.63%, on 4,397 volume with 20 trades. The average volume for the last 60 days is 59,035 and the stock's 52-week low/high is $2.44/$8.45.

Recent News

chart

Marijuana Company of America Inc. (OTC: MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America Inc. (OTC: MCOA) hempSMART™ is committed to the development of industrial hemp-derived cannabidiol (CBD) nutritional products. hempSMART sells products via affiliate marketing and is developing a network of independently driven business owners to distribute hempSMART products.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0305, off by 3.17%, on 5,773,699 volume with 265 trades. The average volume for the last 60 days is 7,765,413 and the stock's 52-week low/high is $0.022/$0.0728.

Recent News

chart

Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF)

The QualityStocks Daily Newsletter would like to spotlight Lithium Chile Inc. (LTMCF).

Lithium Chile (TSX.V: LITH) (OTCQB: LTMCF) this morning issued an update regarding the ongoing drill program at its wholly-owned Ollague project located in the Antofagasta Region of Chile. To view the full press release, visit: http://nnw.fm/7FxEH.

Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF), headquartered in Canada, is advancing one of the largest lithium-rich exploration portfolios in Chile consisting of more than 148,000 hectares covering sections of 13 salars or mineral salt flats and one laguna complex. The company’s wholly owned premier properties include 66 square kilometers on the Salar de Atacama, Chile’s largest mineral salt flat which hosts the world’s highest concentration of lithium brine production and is currently the source of about 35 percent of the world’s lithium production. Lithium Chile also owns a significant copper/gold/silver property portfolio consisting of 28,184 hectares over six different properties.

Lithium Chile’s portfolio in the heart of Chile’s lithium-rich salars includes Salar de Coipasa, Salar de Helados, Salar de Atacama, Salar de Turi Salar de Ollague and Salar de Talar. Surface and near surface salt and brine sampling programs on all properties has been completed. To date, samples of high-grade, near-surface lithium brines at each of these projects are showing excellent chemistry of lithium to potassium and lithium to magnesium ratios. Good chemistry is important as it reduces your overall cost of production. Recent geophysical surveys including T.E.M have been completed on 5 of 6 priority targets and data collected to date has been extremely encouraging.

Lithium Chile has identified multiple high-priority brine target areas at its Atacama and Ollague lithium project areas. These areas display the same geophysical characteristics as the lithium-rich aquifers at Salar de Atacama, home to the world’s largest and highest-grade lithium brine producers. Spanning an area of 1,200 square miles, Salar de Atacama is the world’s third largest salt flat behind Salinas Grandes in Argentina and El Salar de Uyuni in neighboring Bolivia. Exploration drilling and resource definition drilling for these target areas are planned for 2018.

“We are delighted with the discovery of such impressive drill target areas at Atacama and Ollague. The results also follow the recent discovery of a 60km2 target area at another of our top Chilean projects – Helados – where we hope to drill in the second quarter of 2018,” stated President and CEO Steve Cochrane. “We have an aggressive multi-project drill program planned for this year, which includes all three of these exciting projects and we look forward to sharing drill results as they come through.”

Global demand for lithium-ion batteries is expected to surpass US$53 billion by 2024 as governments around the world aggressively seek to ban gas-powered vehicles and major automakers invest billions in new technology and electric vehicles powered by lithium-ion batteries. Chile’s mining-friendly jurisdiction offers Lithium Chile a clear, streamlined permitting process that significantly lowers the cost of lithium production to around $1,800/ton as compared to Australia’s $5,000/ton.

Lithium Chile is led by an experienced team with strong Chilean connections. Cochrane’s 36 years of investment industry experience have primarily been focused on the mining sector. During this time, he raised more than US$500 million for a variety of small cap public companies in various businesses and industry sectors including mining.

Terry Walker, P.Geol., vice president of exploration and chief geologist, is a highly experienced geologist. He has spent over 25 years in Chile’s mining industry and is well connected throughout the sector. Walker is co-founder of GeoServicios Piedra Dorada, an exploration and development services company focused on Latin America. He is a Qualified Person for the North American and Australian stock exchanges.

Lithium Chile is well funded and driven by a top-tier team with more than 100 years of combined experience in financing, mining exploration and development in the natural resources sector.

Lithium Chile Inc. (LTMCF), closed the day's trading session at $0.62, off by 7.19%, on 15,025 volume with 11 trades. The average volume for the last 60 days is 44,960 and the stock's 52-week low/high is $0.535/$0.97.

Recent News

chart

First Cobalt Corp. (TSX-V: FCC) (OTCQX: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF).

Cobalt exploration and development company First Cobalt’s (TSX.V: FCC) (OTCQX: FTSSF) drilling program in Idaho is exploring a promising mineral strike for important tech-friendly metal. To view the full article, visit: http://nnw.fm/G5g0G.

First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance.

First Cobalt Corp. (FTSSF), closed the day's trading session at $0.256, off by 5.92%, on 365,744 volume with 95 trades. The average volume for the last 60 days is 203,987 and the stock's 52-week low/high is $0.2644/$1.3041.

Recent News

chart

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF).

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” ABcann Global CEO Barry Fishman said.

ABcann Global owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

ABcann has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by ABcann’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting ABcann’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

ABcann’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with ABcann’s philosophy of quality and innovation.

ABcann’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, ABcann also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

ABcann Global (ABCCF), closed the day's trading session at $0.889, up 2.21%, on 95,649 volume with 112 trades. The average volume for the last 60 days is 236,269 and the stock's 52-week low/high is $0.65/$3.2929.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.